Siemens Healthineers’ Varian has introduced the next-generation microwave ablation solution, IntelliBlate, in Europe to treat soft tissue tumours.

西门子医疗旗下的瓦里安在欧洲推出了新一代微波消融解决方案 IntelliBlate，用于治疗软组织肿瘤。

Tailored to offer predictability and control, the CE-marked solution is said to provide European clinicians and patients with an intuitive, integrated, and minimally invasive treatment alternative.

该CE认证的解决方案据说为欧洲临床医生和患者提供了一种直观、集成且微创的治疗选择，旨在提供可预测性和控制性。

Go deeper with GlobalData

深入探索GlobalData

Reports

报告

Radiosurgery Systems Market Size (Value, Volume, ASP) by Segments, ...

放射外科系统市场规模（价值、数量、平均售价）按细分市场，...

Reports

报告

Innovation in Healthcare: Thermal Ablation Instruments

医疗创新：热消融仪器

Data Insights

数据洞察

The gold standard of business intelligence.

商业智能的黄金标准。

Find out more

了解更多

Varian noted that this therapeutic device enhances Siemens Healthineers’ imaging and software solution suite, which includes myAblation Guide, myNeedle Laser guidance system, and ultrasound for treatment management.

瓦里安指出，这种治疗设备增强了西门子医疗的成像和软件解决方案套件，其中包含myAblation Guide、myNeedle Laser引导系统以及用于治疗管理的超声波。

The addition of the device, which generates controlled spherical ablation zones for predictable treatment outcomes, facilitates clinicians in planning, placing, treating, monitoring, and confirming ablation therapy within a single environment, streamlining workflow.

该设备的增加能够生成受控的球形消融区，以实现可预测的治疗效果，帮助临床医生在单一环境中规划、放置、治疗、监测和确认消融疗法，从而简化工作流程。

The Ximitry probe, a new feature of IntelliBlate, includes thermocouples for continuous temperature monitoring, providing clinicians with real-time data to inform treatment decisions.

Ximitry探头是IntelliBlate的一项新功能，包含用于持续温度监测的热电偶，为临床医生提供实时数据以指导治疗决策。

The system’s compact and portable design, with two generators in one system, features an intuitive interface for quick setup and pre-programmed settings, decreasing procedural hurdles.

该系统紧凑便携，集两个发生器于一体，具有直观的界面以便快速设置和预编程设置，减少了操作障碍。

GlobalData Strategic Intelligence

全球数据战略情报

US Tariffs are shifting - will you react or anticipate?

美国关税正在变化——你会做出反应还是提前预料？

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

不要让政策变化让你措手不及。通过实时数据和专家分析保持主动性。

By GlobalData

全球数据

Learn more about Strategic Intelligence

了解有关战略情报的更多信息

Last year, the US Food and Drug Administration (FDA)

去年，美国食品和药物管理局 (FDA)

granted 510(k) clearance

授予510(k)许可

for the IntelliBlate microwave ablation system.

适用于IntelliBlate微波消融系统。

The company noted that following its FDA market clearance last year, IntelliBlate’s entry into the European market coincides with increasing clinical evidence supporting thermal ablation.

公司指出，继去年获得FDA市场 clearance后，IntelliBlate进入欧洲市场恰逢越来越多的临床证据支持热消融技术。

The Phase III COLLISION trial highlighted thermal ablation’s effectiveness, comparable to surgical resection, in the treatment of colorectal liver metastases with fewer complications and shorter hospital stays.

III期COLLISION试验强调了热消融在治疗结直肠肝转移中的有效性，其效果与手术切除相当，但并发症更少，住院时间更短。

Varian interventional solutions president Franck Facchini said: “The results of the COLLISION trial mark a milestone in how we think about ablation. We have reached the point where the clinical evidence unrefutably supports the use of thermal ablation as a first-line treatment option, and not just an option for patients who cannot undergo surgery..

瓦里安介入解决方案总裁 Franck Facchini 表示：“COLLISION 试验的结果标志着我们对消融的看法有了一个里程碑。我们已经到了临床证据无可辩驳地支持将热消融作为一线治疗选择的阶段，而不仅仅是不能接受手术的患者的选项。”

“IntelliBlate was designed to meet this shift in care, combining precision with intelligent software and imaging in a solution that fits seamlessly into modern cancer care workflows.”

“IntelliBlate 旨在满足这种护理模式的转变，将精确性与智能软件和成像相结合，提供一个无缝融入现代癌症护理工作流程的解决方案。”